Lead Author	Year	Journal	Institution	Study Type	Level of Evidence	Number of Patients	Liposomal Bupivacaine Dose Given	Concurrent Nerve Block (Y/N + Nerve Block Type)	Comparison Group	Outcome Measured	1-2 Sentence Conclusion
Okoroha, K	2016	Arthroscopy - Journal of Arthroscopic and Related Surgery	Henry Ford Hospital, Detroit, Michigan	Randomized control trial	I	85	20 mL of LB (266 mg) mixed with 10 mL of saline	No	Received a single shot of 40 mL of 0.5% ropivacaine	Daily pain difference	The patients treated with LB had increased pain levels in the initial postoperative hours when compared with FNB. After the acute postoperative period, LB provided similar pain control compared with FNB.
Premkumar, A	2016	American Journal of Sports Medicine	Emory Orthopaedics and Spine Center	Randomized control trial	I	32	20 mL Exparel (1 vial of bupivacaine liposome injectable suspension). Injections were at the hamstring graft sites and port sites (not periarticular).	No	Received 20 mL 0.5% bupivacaine HCl and 20 mL 0.9% injectable saline	Efficacy of liposomal bupivacaine compared to bupivacaine HCL.	There were comparable outcomes with 0.25% bupivacaine HCl at a 200-fold lower cost than liposomal bupivacaine.
Stryder, B	2021	Orthopedics	Med-Star Washington Hospital Center	Randomized control trial	I	67	20 mL of LB (266 mg)	No	Received Catheter-based peripheral nerve block	Quantity of opioids prescribed to patients who received LB	Patients who received liposomal bupivacaine as part of multimodal pain management had significantly fewer opioid prescriptions.
Keller, R	2018	Knee surgery, sports traumatology, arthroscopy	Ascension Crittenton Hospital	Randomized control trial	I	42	20 mL of LB	No	Received femoral nerve block	Postoperative pain levels and opioid consumption	Injecting the posterior capsule of the knee with LB significantly reduced pain in the early postoperative period as well as the total number of opiate medications taken by patients recovering from ACLR.